AUTL
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- NICE recommends AUCATZYL® (obecabtagene autoleucel) as a treatment option for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL)Nov 25, 2025
- Autolus Therapeutics announces first patient dosed in Phase 1 trial of Obecabtagene Autoleucel (Obe-Cel) in patients with progressive multiple sclerosisOct 20, 2025
- Autolus Therapeutics' CAR T therapy AUCATZYL® (obecabtagene autoleucel) granted European marketing authorization for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemiaJul 21, 2025
- Autolus presents long-term data from FELIX study showing potential for durable remission with Obe-Cel in R/R B-ALL at EHA 2025Jun 12, 2025